{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:40:59Z","timestamp":1762980059014,"version":"3.45.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.euros.2021.05.007","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T10:18:13Z","timestamp":1622110693000},"page":"77-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The Uro-oncology Patient and Vaccination Against SARS-CoV-2"],"prefix":"10.1016","volume":"29","author":[{"given":"Moises","family":"Rodriguez Socarr\u00e1s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-3035","authenticated-orcid":false,"given":"Juan","family":"G\u00f3mez Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Puente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Moreno-Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2021.05.007_bib0005","unstructured":"Johns Hopkins University. Coronavirus resource center. https:\/\/coronavirus.jhu.edu\/."},{"key":"10.1016\/j.euros.2021.05.007_bib0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2021.05.007_bib0015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2021.05.007_bib0020","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/anae.15458","article-title":"Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study","volume":"76","author":"COVIDSurg Collaborative","year":"2021","journal-title":"Anaesthesia"},{"key":"10.1016\/j.euros.2021.05.007_bib0025","unstructured":"American Cancer Society COVID-19 vaccines in people with cancer. www.cancer.org\/treatment\/treatments-and-side-effects\/physical-side-effects\/low-blood-counts\/infections\/covid-19-vaccines-in-people-with-cancer.html."},{"key":"10.1016\/j.euros.2021.05.007_bib0030","unstructured":"Fight Bladder Cancer. Covid-19 vaccination programme. https:\/\/fightbladdercancer.co.uk\/get-help\/covid-19-coronavirus."},{"key":"10.1016\/j.euros.2021.05.007_bib0035","unstructured":"European Society for Medical Oncology. Immune efficiency, interaction with therapy and administration of SARS CoV2 vaccine in patients with cancer. https:\/\/webinars.esmo.org\/esmo-webinar-immune-efficiency-interactions-therapy-and-administration-sars-cov-2-vaccine-patients."},{"key":"10.1016\/j.euros.2021.05.007_bib0040","unstructured":"London School of Hygiene and Tropical Medicine. COVID-19 vaccine tracker. https:\/\/vac-lshtm.shinyapps.io\/ncov_vaccine_landscape\/."},{"key":"10.1016\/j.euros.2021.05.007_bib0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/07357907.2021.1885596","article-title":"Challenges and opportunities for COVID-19 vaccines in patients with cancer","volume":"39","author":"Kuderer","year":"2021","journal-title":"Cancer Investig"},{"key":"10.1016\/j.euros.2021.05.007_bib0050","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01240-w","article-title":"COVID-19 vaccination: the VOICE for patients with cancer","volume":"27","author":"van der Veldt","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.euros.2021.05.007_bib0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2021.05.007_bib0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2021.03.030","article-title":"SARS-CoV-2 vaccination for patients with solid cancer: review and point of view of a French oncology inter-group (CGO, TNCD, UNICANCER)","volume":"150","author":"Tougeron","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2021.05.007_bib0065","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41416-020-01219-3","article-title":"COVID-19 vaccine race: watch your step for cancer patients","volume":"124","author":"Fanciullino","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euros.2021.05.007_bib0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.euros.2021.05.007_bib0075","unstructured":"European Society for Medical Oncology. ESMO statements for vaccination against COVID-19 in patients with cancer. www.esmo.org\/covid-19-and-cancer\/covid-19-vaccination."},{"key":"10.1016\/j.euros.2021.05.007_bib0080","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.19.00495","article-title":"Safety of influenza vaccine in patients with cancer receiving pembrolizumab","volume":"16","author":"Failing","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.euros.2021.05.007_bib0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciz202","article-title":"Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors","volume":"70","author":"Chong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.euros.2021.05.007_bib0090","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2018.09.012","article-title":"Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events","volume":"104","author":"Wijn","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2021.05.007_bib0095","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2020.03.290","article-title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","volume":"31","author":"Bayle","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2021.05.007_bib0100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdr141","article-title":"Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and\/or targeted therapy: the VACANCE study","volume":"23","author":"Rousseau","year":"2012","journal-title":"Ann Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168321000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168321000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:05:48Z","timestamp":1762977948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168321000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":20,"alternative-id":["S2666168321000999"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2021.05.007","relation":{},"ISSN":["2666-1683"],"issn-type":[{"type":"print","value":"2666-1683"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Uro-oncology Patient and Vaccination Against SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2021.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}